Comparison of the efficay and side effects of nebulized oral pulmicort and inhaler budesonide in patients with eosinophilic esophagitis

Not Applicable

Recruiting

• Conditions: eosinophilic esophagitis.; Eosinophilic esophagitis; K20.0

• Registration Number: IRCT20191211045703N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Pediatric patients with eosinophilic esophagitis
consent form parents
proton pump consumption
Adherence to the treatment protocols of this study

Exclusion Criteria

history of systemic corticosteroids drugs using
history of systemic underlying diseases
Adrenal insufficiency history

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The effect of oral Budesonide nebulizer on improving Eosinophilic Esophagitis. Timepoint: Patients in the oral Budesonide nebulizer group will receive 1 puff twice a day.If the effectiveness of the drug is not observed after 8 weeks, patients will receive 2 puffs twice a day.Then during weeks 4,12,8 and 16 patients will be followed up and examined. Method of measurement: At the beginning of the study and after the 16th week, patients will be re-examined for histological and tissue pathology, as well as blood eosinophil counts and cortisol examination by Enzyme-linked immunosorbent test at 8 a.m.There will also be a routine laboratory test, such as hematology and biochemistry.